2026 Q2 - tulosraportti
21 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 081 | - | - | ||
| 919 | - | - | ||
| 3 281 | - | - | ||
| 30 | - | - | ||
| 22 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenRelax completely, guys! One day we will all be commenting on rockets and upward-trending graphs! Wiklund has us all!
·2 t sittenI believe many are reading CRNA from the wrong angle. The market sees CAR-T and a new share issue. I see something else: a company that now has capital to build a larger ecosystem around its technology. The latest 200 million NOK is not just "financing to survive". The company has indicated that the capital can also be used to gain access to complementary vector and delivery technologies through licensing, acquisitions, or M&A. And then the question becomes far more interesting than today's share price: What if Circio is not trying to develop a single product, but to control several of the components that can make the platform commercially applicable? If they succeed in combining circVec with the right delivery technology, the story could become bigger than just CAR-T. Then we could potentially be talking about a platform with multiple possible applications and several potential partners. This is what I'm focusing on now: Not how much money Circio has in its account, but what they actually do with the capital. The right technology, agreement, or partner could become far more important than any short-term price movement. In biotech, potential is often priced in early – but the real repricing comes when the potential starts to turn into documentation. Therefore, my question about CRNA is no longer just: "Will the stock rise?" The interesting question is: "What can Circio actually become if they succeed?" And that is a significant difference.
I appreciate such good posts🙂 Objective, informative, insightful and logical. That's good, nice to get for us "mortal" investors. Because truly understanding what Bio tech and Circio's technology is all about, those are complicated matters. Myself included But I listen to good and objective information. Educational.
·3 t sittenWh-wh-what do y-you th-th-think about the stock? Sorry for the stuttering.
I think I have 6.000 and if it hits 9kr then I'll just buy 4.000 more so it'll be a bit more fun to watch it move 🤣 And when my gut feeling tells me to, I'll sell 🤣
·5 t sitten · MuokattuExciting to think about the patent application Circio submitted to EPO in May. Maybe an answer will come eventually?? (Don't know how long something like that takes) The most important thing, of course, is that a patent in itself does not mean that the technology is commercially proven. But if the data continues to be good, while Circio gets stronger patent protection, it should be positive in any licensing negotiations with larger companies.
·6 t sittenManagement had two choices: 1) jump into the car-t race with immediate force. 2) let China thunder on while the rest stand on the platform watching. I must honestly admit I am grateful that management is just pushing through, even if the stock price today is tough, they probably don't care about it - and for good reason. Why should they care about short-term fluctuations in the stock price when the upside is to be part of developing future technology. An exceptionally strong move from management, with short-term negstive outcomes for small shareholders… from a larger perspective, this is gold
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
21 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenRelax completely, guys! One day we will all be commenting on rockets and upward-trending graphs! Wiklund has us all!
- ·2 t sittenI believe many are reading CRNA from the wrong angle. The market sees CAR-T and a new share issue. I see something else: a company that now has capital to build a larger ecosystem around its technology. The latest 200 million NOK is not just "financing to survive". The company has indicated that the capital can also be used to gain access to complementary vector and delivery technologies through licensing, acquisitions, or M&A. And then the question becomes far more interesting than today's share price: What if Circio is not trying to develop a single product, but to control several of the components that can make the platform commercially applicable? If they succeed in combining circVec with the right delivery technology, the story could become bigger than just CAR-T. Then we could potentially be talking about a platform with multiple possible applications and several potential partners. This is what I'm focusing on now: Not how much money Circio has in its account, but what they actually do with the capital. The right technology, agreement, or partner could become far more important than any short-term price movement. In biotech, potential is often priced in early – but the real repricing comes when the potential starts to turn into documentation. Therefore, my question about CRNA is no longer just: "Will the stock rise?" The interesting question is: "What can Circio actually become if they succeed?" And that is a significant difference.I appreciate such good posts🙂 Objective, informative, insightful and logical. That's good, nice to get for us "mortal" investors. Because truly understanding what Bio tech and Circio's technology is all about, those are complicated matters. Myself included But I listen to good and objective information. Educational.
- ·3 t sittenWh-wh-what do y-you th-th-think about the stock? Sorry for the stuttering.I think I have 6.000 and if it hits 9kr then I'll just buy 4.000 more so it'll be a bit more fun to watch it move 🤣 And when my gut feeling tells me to, I'll sell 🤣
- ·5 t sitten · MuokattuExciting to think about the patent application Circio submitted to EPO in May. Maybe an answer will come eventually?? (Don't know how long something like that takes) The most important thing, of course, is that a patent in itself does not mean that the technology is commercially proven. But if the data continues to be good, while Circio gets stronger patent protection, it should be positive in any licensing negotiations with larger companies.
- ·6 t sittenManagement had two choices: 1) jump into the car-t race with immediate force. 2) let China thunder on while the rest stand on the platform watching. I must honestly admit I am grateful that management is just pushing through, even if the stock price today is tough, they probably don't care about it - and for good reason. Why should they care about short-term fluctuations in the stock price when the upside is to be part of developing future technology. An exceptionally strong move from management, with short-term negstive outcomes for small shareholders… from a larger perspective, this is gold
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 081 | - | - | ||
| 919 | - | - | ||
| 3 281 | - | - | ||
| 30 | - | - | ||
| 22 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
21 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenRelax completely, guys! One day we will all be commenting on rockets and upward-trending graphs! Wiklund has us all!
- ·2 t sittenI believe many are reading CRNA from the wrong angle. The market sees CAR-T and a new share issue. I see something else: a company that now has capital to build a larger ecosystem around its technology. The latest 200 million NOK is not just "financing to survive". The company has indicated that the capital can also be used to gain access to complementary vector and delivery technologies through licensing, acquisitions, or M&A. And then the question becomes far more interesting than today's share price: What if Circio is not trying to develop a single product, but to control several of the components that can make the platform commercially applicable? If they succeed in combining circVec with the right delivery technology, the story could become bigger than just CAR-T. Then we could potentially be talking about a platform with multiple possible applications and several potential partners. This is what I'm focusing on now: Not how much money Circio has in its account, but what they actually do with the capital. The right technology, agreement, or partner could become far more important than any short-term price movement. In biotech, potential is often priced in early – but the real repricing comes when the potential starts to turn into documentation. Therefore, my question about CRNA is no longer just: "Will the stock rise?" The interesting question is: "What can Circio actually become if they succeed?" And that is a significant difference.I appreciate such good posts🙂 Objective, informative, insightful and logical. That's good, nice to get for us "mortal" investors. Because truly understanding what Bio tech and Circio's technology is all about, those are complicated matters. Myself included But I listen to good and objective information. Educational.
- ·3 t sittenWh-wh-what do y-you th-th-think about the stock? Sorry for the stuttering.I think I have 6.000 and if it hits 9kr then I'll just buy 4.000 more so it'll be a bit more fun to watch it move 🤣 And when my gut feeling tells me to, I'll sell 🤣
- ·5 t sitten · MuokattuExciting to think about the patent application Circio submitted to EPO in May. Maybe an answer will come eventually?? (Don't know how long something like that takes) The most important thing, of course, is that a patent in itself does not mean that the technology is commercially proven. But if the data continues to be good, while Circio gets stronger patent protection, it should be positive in any licensing negotiations with larger companies.
- ·6 t sittenManagement had two choices: 1) jump into the car-t race with immediate force. 2) let China thunder on while the rest stand on the platform watching. I must honestly admit I am grateful that management is just pushing through, even if the stock price today is tough, they probably don't care about it - and for good reason. Why should they care about short-term fluctuations in the stock price when the upside is to be part of developing future technology. An exceptionally strong move from management, with short-term negstive outcomes for small shareholders… from a larger perspective, this is gold
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 081 | - | - | ||
| 919 | - | - | ||
| 3 281 | - | - | ||
| 30 | - | - | ||
| 22 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt